177Lu-PSMA Therapy

177Lu-PSMA Therapy is an advanced, targeted treatment for prostate cancer. It combines the radioactive isotope Lutetium-177 (177Lu) with a molecule called PSMA (Prostate-Specific Membrane Antigen). When administered, the therapy binds to PSMA receptors found on prostate cancer cells. The Lutetium emits high-energy particles that selectively damage these cancer cells while minimizing impact on surrounding tissue.

‍Referral Process
Specialists should email referrals for consideration of 177Lu-PSMA therapy to appointments@mtic.net.au
Please include:
- Recent medical history
- Imaging results
- Pathology reports
Our team will contact the patient to arrange a consultation and assess suitability for treatment.

‍Procedure Details
177Lu-PSMA therapy is performed as a day procedure in our dedicated therapy suite. The treatment is delivered by a multidisciplinary team, including Nuclear Medicine Technologists, Nurses, and Nuclear Medicine Physicians